News/Resources

News

see all news

Proteomedix announces grant of U.S. patent on Proclarix®.

July 5, 2022

New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

June 29, 2022

Publications

see all publications

Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI.

Campistol M, Morote J, Triquell M, Regis L, Celma A, Torres I, Semidey ME, Mast R, Santamaría A, Planas J, Trilla E. Cancers 14, 2702 (2022). https://dx.doi.org/10.3390/cancers14112702

Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?

Morote J, Campistol M, Regis L, Celma A, Torres I, Semidey ME, Roche S, Mast R, Santamaría A, Planas J, Trilla E. Int J Biol Markers 2022 Feb 24; doi: 10.1177/03936155221081537.